MODIFIED INTERFERON-ALPHA-2 HAVING REDUCED IMMUNOGENICITY

The present disclosure is directed to compositions comprising modified interferon-α2 polypeptides having interferon-α2 activity and reduced immunogenicity. In aspects, said modified interferon-α2 polypeptides are hyperglycosylated, such as by addition of a GM-CSF-derived peptide sequence with multiple O-glycosylation sites. Furthermore, the present disclosure provides compositions comprising a nucleic acid molecule encoding said modified interferon-α2. The present disclosure also provides compositions comprising a recombinant protein expression cell line comprising said nucleic acid molecule encoding said modified interferon-α2; wherein said recombinant protein expression cell comprises a plasmid or vector containing said nucleic acid molecule. Also disclosed are pharmaceutical compositions comprising a modified interferon-α2 having interferon-α2 activity with reduced immunogenicity, as well as methods of use of said pharmaceutical formulations for treatment of medical conditions in a subject.